OSU-CG5

OSU-CG5 is a small molecule energy restriction mimetic (ERM) that functions as a non-ATP-competitive inhibitor of the FOXM1 (Forkhead Box M1) transcription factor. Developed by researchers at The Ohio State University, OSU-CG5 is designed to target the metabolic vulnerabilities of cancer cells, specifically the Warburg effect, by suppressing FOXM1-mediated oncogenic signaling. Preclinical research in pancreatic cancer cell lines (such as Panc-1 and MiaPaca) has shown that OSU-CG5 reduces cell survival and FOXM1 expression without directly altering glucose uptake or Glut1 protein levels. It represents a therapeutic strategy to mimic the anti-tumorigenic effects of calorie restriction through pharmacological intervention.